[go: up one dir, main page]

AU2001280056A1 - Pharmaceutical compositions and methods useful for modulating angiogenesis - Google Patents

Pharmaceutical compositions and methods useful for modulating angiogenesis

Info

Publication number
AU2001280056A1
AU2001280056A1 AU2001280056A AU8005601A AU2001280056A1 AU 2001280056 A1 AU2001280056 A1 AU 2001280056A1 AU 2001280056 A AU2001280056 A AU 2001280056A AU 8005601 A AU8005601 A AU 8005601A AU 2001280056 A1 AU2001280056 A1 AU 2001280056A1
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
methods useful
modulating angiogenesis
angiogenesis
mammalian tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280056A
Inventor
Gal Akiri
Stela Gengrovitch
Gera Neufeld
Zahava Vadasz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research and Development Foundation Ltd
Original Assignee
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research and Development Foundation Ltd filed Critical Technion Research and Development Foundation Ltd
Publication of AU2001280056A1 publication Critical patent/AU2001280056A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method of modulating angiogenesis in a mammalian tissue is provided. The method including administering into the mammalian tissue a molecule capable of modifying a tissue level and/or activity of at least one type of lysyl-oxidase to thereby modulate angiogenesis in the mammalian tissue.
AU2001280056A 2000-08-08 2001-08-07 Pharmaceutical compositions and methods useful for modulating angiogenesis Abandoned AU2001280056A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22373900P 2000-08-08 2000-08-08
US60/223,739 2000-08-08
PCT/IL2001/000728 WO2002011667A2 (en) 2000-08-08 2001-08-07 Pharmaceutical compositions and methods useful for modulating angiogenesis

Publications (1)

Publication Number Publication Date
AU2001280056A1 true AU2001280056A1 (en) 2002-02-18

Family

ID=22837793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280056A Abandoned AU2001280056A1 (en) 2000-08-08 2001-08-07 Pharmaceutical compositions and methods useful for modulating angiogenesis

Country Status (9)

Country Link
EP (4) EP2078531B1 (en)
AT (1) ATE493147T1 (en)
AU (1) AU2001280056A1 (en)
CY (3) CY1111869T1 (en)
DE (1) DE60143754D1 (en)
DK (4) DK2359854T3 (en)
ES (4) ES2437093T3 (en)
PT (4) PT2078531E (en)
WO (1) WO2002011667A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
US20030224989A1 (en) * 2002-02-12 2003-12-04 Kerry Quinn Compositions and methods for treatment of osteoarthritis
FR2855968B1 (en) 2003-06-13 2012-11-30 Coletica STIMULATION OF THE SYNTHESIS AND ACTIVITY OF A LYSYL OXIDASE-LIKE LOXL ISOFORM TO STIMULATE THE FORMATION OF ELASTIC FIBERS
EP1706139A4 (en) 2004-01-23 2009-06-17 Massachusetts Eye & Ear Infirm Lysyl oxidase-like 1 (loxl1) and elastogenesis
WO2006128740A2 (en) * 2005-06-02 2006-12-07 Centelion Anti-vascular methods and therapies employing lysyl oxidase inhibitors
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
PL2182981T3 (en) 2007-08-02 2013-06-28 Gilead Biologics Inc Methods and compositions for treatment and diagnosis of fibrosis
DE102007051006A1 (en) * 2007-10-25 2009-04-30 Lanxess Deutschland Gmbh Stable, synergistic mixtures
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
RU2012110585A (en) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. CATALYTIC DOMAINS OF LYSYLOXIDASE AND LOXL2
SG183174A1 (en) 2010-02-04 2012-09-27 Gilead Biologics Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
KR102726837B1 (en) * 2021-09-29 2024-11-07 (주)케어젠 Peptide Having Anti-Aging Activity and Uses Thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DK51092D0 (en) 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6300092B1 (en) * 1999-01-27 2001-10-09 Millennium Pharmaceuticals Inc. Methods of use of a novel lysyl oxidase-related protein
AU2001261194A1 (en) * 2000-05-03 2001-11-12 University Of Hawaii Novel members of the lysyl oxidases family of amine oxidases related applications
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis

Also Published As

Publication number Publication date
PT2078531E (en) 2012-08-06
WO2002011667A3 (en) 2003-03-27
ES2387329T3 (en) 2012-09-20
DE60143754D1 (en) 2011-02-10
EP2078531B1 (en) 2012-05-30
EP2078531A3 (en) 2010-01-20
ES2437093T3 (en) 2014-01-08
DK1315519T3 (en) 2011-04-11
EP2078531A2 (en) 2009-07-15
ES2440932T3 (en) 2014-01-31
EP1315519A2 (en) 2003-06-04
CY1113142T1 (en) 2016-04-13
ES2358581T3 (en) 2011-05-12
DK2359854T3 (en) 2013-11-04
DK2359853T3 (en) 2013-12-09
EP1315519A4 (en) 2005-09-14
EP2359854B1 (en) 2013-10-09
ATE493147T1 (en) 2011-01-15
CY1111869T1 (en) 2015-11-04
PT2359854E (en) 2013-11-22
CY1114734T1 (en) 2016-12-14
EP2359854A1 (en) 2011-08-24
HK1131912A1 (en) 2010-02-12
EP1315519B1 (en) 2010-12-29
HK1161115A1 (en) 2012-08-24
HK1161113A1 (en) 2012-08-24
WO2002011667A2 (en) 2002-02-14
PT1315519E (en) 2011-03-17
DK2078531T3 (en) 2012-09-10
EP2359853A1 (en) 2011-08-24
EP2359853B1 (en) 2013-11-06
PT2359853E (en) 2013-12-26

Similar Documents

Publication Publication Date Title
CY1114734T1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS USED FOR VASCULAR ADJUSTMENT
AU2490297A (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
AU7213698A (en) The use of fumaric acid derivatives
CY1115583T1 (en) Packaging Containing Lysosomal Alpha-Lactosidase A Mutant / F for Therapeutic Treatment of FABRY Disease
GR3032673T3 (en) Use of an effective quantitiy of active substances for the treatment of mixed skin.
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
TW225532B (en)
EP0824910A3 (en) Use of a Krill Enzyme for the Treatment of Dental Plaque
CA2209695A1 (en) Use of a polyholoside in a composition to promote desquamation and the composition containing it
ATE206914T1 (en) USE OF URSOLIC ACID TO PRODUCE A MEDICINAL PRODUCT FOR SUPPRESSING METASTASIS
GR3006815T3 (en)
ATE231388T1 (en) LONG-ACTING AGENT FOR RECTAL ADMINISTRATION
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
AU2323095A (en) Lactam derivatives useful for pharmaceutical purposes
AU3024389A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
AU6932691A (en) Administration method of antithrombin
AU5157596A (en) Biodegradable device
AU2420001A (en) Methods and compositions for the treatment of pain
CA2199624A1 (en) Polymerizable aromatic carboxylic acids and carboxyanhydrides with cyclic carbonate groups, as well as preparations containing these compounds
ATE297749T1 (en) USE OF PEPTIDIC BRADYKININ ANTAGONISTS FOR THE PRODUCTION OF MEDICINAL PRODUCTS
WO2001022917A3 (en) Effervescent compositions comprising nimesulide
FR2772616B1 (en) DEPIGMENTING COMPOSITION
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
AU2357992A (en) Use of combination of a gel and a solution both containing an organic acid for cleaning dentures
EP0951904A3 (en) Agent for enhancing dermal microcirculation